The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
A significant genome-wide association study on the nonalcoholic fatty liver disease (NAFLD) has just been published in Nature Genetics by researchers from Amgen subsidiary deCODE Genetics.
A long-running debate in gastroenterology has been settled by WEHI researchers who have shown that prevalent liver diseases are not caused by inflammatory cell death as previously believed.
The immune system may attack the liver when fat builds up there. The chemical that triggers these responses has been discovered by Weill Cornell Medicine researchers in a recent study, and this information helps to explain the dynamics of liver damage that can accompany type 2 diabetes and obesity.
Researchers at Cedars-Sinai have created a way to determine the human gut microorganisms that are most likely to cause a variety of inflammatory disorders, including obesity, liver disease, inflammatory bowel disease, cancer, and several neurological conditions.
A multidisciplinary group of researchers at the University of California San Diego School of Medicine have advanced investigations into the genetic causes of NAFLD in children.
Other vertebrates, such as fish and lizards, can regenerate organs more effectively than mammals. Salk researchers have discovered a mechanism to partially restore the young condition of liver cells, allowing them to repair damaged tissue at a quicker rate than previously thought.
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery.
Non-alcoholic fatty liver disease (NAFLD), commonly known as fatty liver disease, is a prevalent disease frequently seen in obese people. Having high fat content in the liver is detrimental as it is strongly associated with severe health problems like diabetes, high blood pressure, and liver cancer.
The in-built mechanism of recycling dead or poisonous material to preserve the health of human cells is critical to general health.
A vaccine for hepatitis C has eluded scientists for more than 30 years, for several reasons. For one, the virus that causes the disease comes in many genetic forms, complicating the creation of a widely effective vaccine.
In a breakthrough discovery, scientists from The University of Texas Health Science Center at San Antonio today reported that inhibiting a liver enzyme in obese mice decreased the rodents' appetite, increased energy expenditure in adipose (fat) tissues and resulted in weight loss.
Anti-fibrotic therapy is still a medical necessity in the treatment of chronic liver disease in humans. The anti-fibrotic activity of globin family members in hepatic stellate cells (HSCs), the principal cell type involved in liver fibrosis, was reported by a research group led by Professor Norifumi Kawada of Osaka Metropolitan University (OMU).
A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.
A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.
Professor Yuichi Oike and his group of researchers recently produced a peptide vaccine that mitigates conditions of dyslipidemia.
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver unrelated to alcohol abuse or other liver diseases.
Associate Professor Tamer Önder created and analyzed the hepatic organoid culture system utilizing human induced pluripotent stem cell as an intermediate.
Research demonstrated that obese individuals with active brown fat possess a healthier metabolism and utilize more energy than obese people without.
For the first time, DNA mutations in liver cells have been identified that impact metabolism and insulin sensitivity in patients with liver disease.
A commonly available oral diuretic pill approved by the U.S. Food and Drug Administration may be a potential candidate for an Alzheimer's disease treatment for those who are at genetic risk, according to findings published in Nature Aging.